Key Takeaways
Cronos Group Inc. (NASDAQ: CRON) reported first-quarter net revenue of $45.2 million, a 40 percent increase year-over-year, as the company saw record sales in international markets and growth in its Canadian brand portfolio. The company also announced a new $50 million share repurchase program.
"Cronos delivered record net revenue and gross profit in the first quarter, as we continue to execute against our borderless products strategy," Mike Gorenstein, Chairman, President and CEO of Cronos, said in a statement. "In Canada, the Spinach® brand claimed the #1 position in vapes for the first time, while maintaining its outstanding #1 ranking in edibles."
The cannabis company's net income rose 103 percent to $15.7 million, or 4 cents per share, from $7.7 million, or 2 cents per share, in the same period last year. Adjusted EBITDA for the quarter was $5.1 million, a significant improvement from $2.3 million in the first quarter of 2025. The growth was primarily driven by higher gross profit from increased sales volumes and higher average selling prices.
The strong results reflect significant momentum in international markets and sustained growth across product categories, positioning the company for continued growth, Gorenstein said. Cronos holds an industry-leading balance sheet with $822 million in cash and cash equivalents as of March 31, 2026.
Cronos saw significant gains in its brand portfolio. In Canada, the Spinach® brand became the top-selling brand in the vapes category with a 9.8% market share, while also holding its #1 position in edibles with a 20.8% share. The brand's flower products also rose to the #3 spot nationally.
Internationally, the PEACE NATURALS® brand continued its dominance in Israel, marking its ninth consecutive quarter of record net revenue and maintaining its position as the #1 cannabis brand in the country. Net revenue in Israel grew 53% year-over-year. Other international markets, including Europe, saw net revenue grow by 97% compared to the prior-year quarter.
Cronos announced that its Board of Directors has authorized a new share repurchase program of up to $50 million, set to commence on May 14, 2026. This follows the previous program where the company repurchased approximately 13.4 million shares at a cost of $33.5 million.
The company also provided an update on its pending acquisition of CanAdelaar B.V., a leading cannabis producer in the Netherlands. The closing date has been extended to September 9, 2026, to allow for the completion of regulatory clearances. The acquisition is expected to establish a strategic footprint for Cronos in the European adult-use market.
The positive earnings report signals that the company's focus on international expansion and brand-building is yielding significant results. Investors will be watching for the successful closing of the CanAdelaar acquisition and continued market share growth in the upcoming quarters.
This article is for informational purposes only and does not constitute investment advice.
